190 related articles for article (PubMed ID: 31095039)
1. Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.
Martin-Algarra S; Hinshelwood R; Mesnage S; Cebon J; Ferrucci PF; Aglietta M; Neyns B; Chiarion-Sileni V; Lindsay CR; Del Vecchio M; Linardou H; Merelli B; Tonini G; Atkinson V; Freivogel K; Stein D; Dalland L; Lau M; Legenne P; Queirolo P; Millward M
Melanoma Res; 2019 Oct; 29(5):527-532. PubMed ID: 31095039
[TBL] [Abstract][Full Text] [Related]
2. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
[TBL] [Abstract][Full Text] [Related]
3. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
5. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Hauschild A; Grob JJ; Demidov LV; Jouary T; Gutzmer R; Millward M; Rutkowski P; Blank CU; Miller WH; Kaempgen E; Martín-Algarra S; Karaszewska B; Mauch C; Chiarion-Sileni V; Martin AM; Swann S; Haney P; Mirakhur B; Guckert ME; Goodman V; Chapman PB
Lancet; 2012 Jul; 380(9839):358-65. PubMed ID: 22735384
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto P; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
Target Oncol; 2021 Nov; 16(6):789-799. PubMed ID: 34755244
[TBL] [Abstract][Full Text] [Related]
7. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
[TBL] [Abstract][Full Text] [Related]
8. Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.
Yamazaki N; Tsutsumida A; Takahashi A; Namikawa K; Yoshikawa S; Fujiwara Y; Kondo S; Mukaiyama A; Zhang F; Kiyohara Y
J Dermatol; 2018 Apr; 45(4):397-407. PubMed ID: 29399853
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Hauschild A; Ascierto PA; Schadendorf D; Grob JJ; Ribas A; Kiecker F; Dutriaux C; Demidov LV; Lebbé C; Rutkowski P; Blank CU; Gutzmer R; Millward M; Kefford R; Haas T; D'Amelio A; Gasal E; Mookerjee B; Chapman PB
Eur J Cancer; 2020 Jan; 125():114-120. PubMed ID: 31864178
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
11. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
[TBL] [Abstract][Full Text] [Related]
12. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
[TBL] [Abstract][Full Text] [Related]
14. Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma.
Takahashi A; Namikawa K; Nakano E; Yamazaki N
J Dermatol; 2020 Mar; 47(3):257-264. PubMed ID: 31876308
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
[TBL] [Abstract][Full Text] [Related]
16. Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation.
Teshima Y; Kizaki M; Kurihara R; Kano R; Harumiya M
Int J Clin Oncol; 2020 Oct; 25(10):1870-1878. PubMed ID: 32699976
[TBL] [Abstract][Full Text] [Related]
17. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
[TBL] [Abstract][Full Text] [Related]
18. Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).
González-Barrallo I; Castellón Rubio VE; Medina J; España S; Mujika K; Majem M; Aguado C; Cabrera Suárez MÁ; Palacio I; Osterloh L; Martínez-Fernández A; García-Castaño A
Melanoma Res; 2022 Oct; 32(5):343-352. PubMed ID: 35762583
[TBL] [Abstract][Full Text] [Related]
19. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
20. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
